ArticleInternational journal of molecular sciences2015
Glucagon Like Peptide-1 (GLP-1) Modulates OVA-Induced Airway Inflammation and Mucus Secretion Involving a Protein Kinase A (PKA)-Dependent Nuclear Factor-κB (NF-κB) Signaling Pathway in Mice.
Article in International journal of molecular sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.
- Pre-admission glucagon-like peptide-1 receptor agonist (GLP-1RA) and mortality from coronavirus disease 2019 (Covid-19): A systematic review, meta-analysis, and meta-regression.Diabetes research and clinical practice · 2021Pooled it
- Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study.BMC pulmonary medicine · 2026Article
- Therapeutic Potential of Glucagon-like Peptide-1 Receptor Agonists in Respiratory Disorders.International journal of molecular sciences · 2026Review
- Obesity and asthma: obesity causes and aggravates asthma across the entire type-2 inflammation spectrum.The European respiratory journal · 2026Review
- GLP-1RAs: antidiabetic drug crossover-new hope for chronic inflammatory airway diseases.Respiratory research · 2026Review
- Antidiabetic drug and chronic respiratory disease in type 2 diabetes: a network meta-analysis and Mendelian randomization analysis.Therapeutic advances in endocrinology and metabolism · 2026Review
- Review
- The Role of GLP-1 Analogues in the Treatment of Obesity-Related Asthma Phenotype.Biomedicines · 2025Review
- Roles of glucagon-like peptide 1 receptor agonists in immune cell biology and autoimmune/autoinflammatory diseases.Cell & bioscience · 2025Review
- Integration of network pharmacology and experimental validation to explore the pharmacological mechanism of andrographolide against asthma.Bioresources and bioprocessing · 2025Article
- The possible effect of anti-diabetic agents GLP-1RA and SGLT-2i on the respiratory system function.Endocrine · 2025Review
- Induced Sputum Transcriptomics Profile and Serum C3 are Associated with Asthma Severity.Journal of asthma and allergy · 2025Article
- Effects of Hypoglycemic Agents on Pulmonary Diseases: A Comprehensive Narrative Review.Journal of inflammation research · 2025Review
- COPD and Metabolic Syndrome: Unanswered Questions and Opportunities for Innovation.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024Article
- Asthma and Hyperglycemia: Exploring the Interconnected Pathways.Diagnostics (Basel, Switzerland) · 2024Review
- Clinical Characteristics of Overweight Patients With Acute Exacerbation Chronic Obstructive Pulmonary Disease (AECOPD).The clinical respiratory journal · 2024Article
- The Role of Peptides in Asthma-Obesity Phenotype.International journal of molecular sciences · 2024Review
- Unraveling the Link between Ιnsulin Resistance and Bronchial Asthma.Biomedicines · 2024Review
- Potential association between obstructive lung diseases and cognitive decline.Frontiers in immunology · 2024Observational
- Role of the cAMP-PKA-NF-κB pathway in Mucin1 over-expression in A549 cells during Respiratory syncytial virus infection.BMC infectious diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asthma is a common chronic pulmonary inflammatory disease, featured with mucus hyper-secretion in the airway. Recent studies found that glucagon like peptide-1 (GLP-1) analogs, including liraglutide and exenatide, possessed a potent anti-inflammatory property through a protein kinase A (PKA)-dependent signaling pathway. Therefore, the aim of current study was to investigate the value of GLP-1 analog therapy liraglutide in airway inflammation and mucus secretion in a murine model of ovalbumin (OVA)-induced asthma, and its underlying molecular mechanism. In our study, BALB/c mice were sensitized and challenged by OVA to induce chronic asthma. Pathological alterations, the number of cells and the content of inflammatory mediators in bronchoalveolar lavage fluid (BALF), and mucus secretion were observed and measured. In addition, the mRNA and protein expression of E-selectin and MUC5AC were analyzed by qPCR and Western blotting. Then, the phosphorylation of PKA and nuclear factor-κB (NF-κB) p65 were also measured by Western blotting. Further, NF-κB p65 DNA binding activity was detected by ELISA. OVA-induced airway inflammation, airway mucus hyper-secretion, the up-regulation of E-selectin and MUC5AC were remarkably inhibited by GLP-1 in mice (all p < 0.01). Then, we also found that OVA-reduced phosphorylation of PKA, and OVA-enhanced NF-κB p65 activation and NF-κB p65 DNA binding activity were markedly improved by GLP-1 (all p < 0.01). Furthermore, our data also figured out that these effects of GLP-1 were largely abrogated by the PKA inhibitor H-89 (all p < 0.01). Taken together, our results suggest that OVA-induced asthma were potently ameliorated by GLP-1 possibly through a PKA-dependent inactivation of NF-κB in mice, indicating that GLP-1 analogs may be considered an effective and safe drug for the potential treatment of asthma in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.